Therapure Bio Contact Presentation Sept 29 08


Published on

Biomanufacturing Services / Contract Manufacturing Biologicals

  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Therapure Bio Contact Presentation Sept 29 08

  1. 1. BioContact Presentation | Fall 2008
  2. 2. of all new products The future of medicine 1 3 /
  3. 3. $51B $87B $25B $89B 2001 Protein therapeutic market 2005 2010 2010 Worldwide mobile technology market
  4. 4. You discovered a protein with blockbuster potential <ul><li>Specific </li></ul><ul><li>Safe </li></ul><ul><li>Targeted </li></ul><ul><li>Efficacious </li></ul><ul><li>Novel </li></ul>
  5. 5. <ul><li>Ultimately, to get your product approved you will invest… </li></ul>You are working hard to develop it <ul><li>11 years </li></ul><ul><li>5 clinical trials </li></ul><ul><li>2,000 patients </li></ul><ul><li>39 patents </li></ul><ul><li>~$1 billion </li></ul>
  6. 6. What about manufacturing ?
  7. 7. Discovery Development Marketing Manufacturing
  8. 8. Scaling up is not easy <ul><li>Simple </li></ul><ul><li>Quick </li></ul><ul><li>Inexpensive </li></ul><ul><li>Milligrams </li></ul>commercial bench <ul><li>Complex </li></ul><ul><li>Long lead times - 4-5 years </li></ul><ul><li>Expensive - $150 + million </li></ul><ul><li>Kilograms </li></ul>
  9. 9. Therapure Biopharma: Overcoming the manufacturing barrier We have 8 INDs under our belts Regulated Established Meadowpine Facility Expensive cGMP compliant Quality Ready to go now Long lead times We know protein purification Complex
  10. 10. <ul><li>your trusted partner </li></ul>for protein manufacturing
  11. 11. Therapure Biopharma Focus <ul><li>Provide clients access to our biomanufacturing capabilities </li></ul><ul><ul><li>Product development </li></ul></ul><ul><ul><li>Protein purification </li></ul></ul><ul><ul><li>Cell culture </li></ul></ul><ul><ul><li>Formulation </li></ul></ul><ul><ul><li>Fill </li></ul></ul><ul><ul><li>Lyophilization </li></ul></ul><ul><ul><li>Finishing </li></ul></ul><ul><li>Advance our pipeline </li></ul><ul><li>TBI 301 Post-liver transplant & acute and chronic HCV </li></ul><ul><li>TBI 302 Hepatocellular carcinoma & metastatic colorectal cancer </li></ul><ul><li>TBI 303 Proprietary protein modification technology </li></ul><ul><li>TBI 304 Chemotherapy-induced anemia </li></ul>
  12. 12. Experienced Management Team <ul><li>Thomas Wellner President and CEO </li></ul><ul><li>Dirk Alkema Vice President, Operations </li></ul><ul><li>Peter Winkley Vice President Finance and Chief Financial Officer </li></ul><ul><li>David Bell Vice President, Drug Development and Chief Scientific Officer </li></ul>
  13. 13. About Us <ul><li>Therapure Biopharma Inc. Canadian-based privately held biopharmaceutical company wholly owned by Catalyst Fund Limited Partnership II and management. </li></ul><ul><li>Catalyst Fund Limited Partnership II A private equity fund with over $1B U.S. in capital that is managed by The Catalyst Capital Group Inc., a Toronto based private equity fund manager. </li></ul>
  14. 14. Ideally located
  15. 15. 90 minute flight to 60% of the U.S. population
  16. 16. Our Unique and Flexible Biomanufacturing Facility
  17. 17. 130,000 square feet <ul><li>5,700 sq.ft. of research laboratories </li></ul><ul><li>6,300 sq.ft. of QC labs </li></ul><ul><li>30,000 sq.ft. clean room manufacturing </li></ul><ul><li>28,000 sq.ft. controlled cGMP warehouse </li></ul><ul><li>2,200 sq.ft. GMP clinical pilot suites </li></ul>
  18. 18. Large Volume Protein Purification
  19. 19. Large Scale Processing Capabilities
  20. 20. Large Volume Storage Capacity
  21. 21. Central Service Chase
  22. 22. CIP Units For Process Equipment
  23. 23. Water For Injection
  24. 24. Purified Water System
  25. 25. Clean Rooms and Access Points to Meet cGMP Requirements
  26. 26. QC Laboratories
  27. 27. Sterile Fill Suite
  28. 28. Support Beyond Manufacturing
  29. 29. Enhanced partnerships Biomanufacturing In-licensing Equity partnerships <ul><li>Late-stage products </li></ul><ul><li>Approved products in new indications </li></ul><ul><li>Possible targeted investment </li></ul>Joint development <ul><li>Innovative financing </li></ul><ul><li>Product co-development </li></ul><ul><li>Process development </li></ul><ul><li>Formulation </li></ul><ul><li>Protein purification </li></ul><ul><li>Fill & finishing </li></ul>Fee for service
  30. 30. Therapure (manufacturing) Therapure (finance) $$ (seed capital) $$ (development fees) protein product interest/options Biotech Equity Partnership
  31. 31. partnership Biotech Therapure Biopharma Product IP/ development Manufacturing IP/ development Joint Development
  32. 32. Therapure Biopharma Inc. <ul><li>Unique and Flexible </li></ul><ul><ul><li>Scale of production </li></ul></ul><ul><ul><li>Range of production </li></ul></ul><ul><li>Expertise </li></ul><ul><ul><li>Scientific </li></ul></ul><ul><ul><li>Manufacturing </li></ul></ul><ul><ul><li>Regulatory </li></ul></ul><ul><li>Financing opportunities </li></ul>
  33. 33. <ul><li>Let </li></ul>bring your biopharmaceutical to the world!